Difference between revisions of "Liang"
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | <span style="font-size:18.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:18.0pt"><span style="line-height:107%"><span style="font-family:">Weak evidence that hyperbaric oxygen may be safe and effective for post-stroke depression.</span></span></span> |
| − | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Objectives:</span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Post-stroke depression (PSD) is common consequence of stroke. However, today the majority of PSD patients remains untreated or inadequately treated, especially in the developing countries. Herein, we performed a meta-analysis to evaluate efficacy and safety of hyperbaric oxygen (HBOT) therapy for PSD.</span></span></span> |
| − | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Patients and methods:</span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Seven electronic databases were comprehensively searched for randomized clinical trials (RCTs) from inception to May 2019. Outcome measures included response rate, depression severity, neurological deficit, physical disability and adverse events.</span></span></span> |
| − | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Results:</span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">A total of 27 RCTs involving 2250 participants were identified. Patients in HBOT group had a higher response rate than patients in control group (response rate: 69.4% vs 51.2%, odds ratio [OR]=2.51, 95% confidence interval [CI] [1.83–3.43], P =0.000).</span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">'''''HBO better for:''''' </span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Hamilton Depression (HAMD) –17 item scores (weighted mean difference [WMD] =−4.33, 95% CI [−4.82 to −3.84], P=0.000)</span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">HAMD-24 item scores (WMD=−4.31, 95% CI [−5.01 to −3.62], P=0.000)</span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">National Institute of Health Stroke Scale (NIHSS) scores (WMD=−2.77, 95% CI [−3.57 to −1.98], P=0.000)</span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Chinese Stroke Scale (CSS) scores (WMD=−3.75, 95% CI [−5.12 to −2.38], P=0.000)</span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Modified Scandinavian Stroke Scale (MASSS) scores (WMD=−3.66, 95% CI [−6.26 to −1.06], P=0.000).</span></span></span> |
| − | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Barthel Index (WMD=10.68, 95% CI [7.98–13.37].</span></span></span> | |
| − | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Patients with HBOT along with antidepressants treatment achieve superior results than patients with antidepressants monotherapy. Patients with HBOT monotherapy achieve a slightly higher response rate than patients with antidepressants monotherapy (OR=1.29, 95% CI [1.04–1.60], P=0.000). Besides, HBOT group reported less adverse events (9.6%vs16.6%, P < 0.05). The most frequent side-effect of HBOT is ear pain (26 cases).</span></span></span> | |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:" | + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Conclusion: </span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Based on our pooled analysis, HBOT is effective and safe therapeutic approach for PSD. However, results should be cautiously interpreted due to a relatively poor methodological quality.</span></span></span> |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Comments:</span></span></span>''' |
| − | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family: | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">1. MA dominated by Chinese studies unavailable to this reviewer to date. Only 1 of 27 included studies published in English and no studies from the Cochrane review are included. This may reflect the non-acute nature of interventions applied in the convalescent period rather than acute stroke.</span></span></span> |
| − | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">2. Authors were only confident of randomisation in 8 of 27 studies and only 1 was blinded.Low quality RCTs likely</span></span></span> | |
| − | + | <span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">3. Conclusions are difficult to assess given the above. Some of the outcome measures apparently improved were assessing function (NIHSS) and QoL (Barthel Index).</span></span></span> | |
| − | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:" | + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Citation:</span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Liang XX, Hao YG, Duan XM, Han XL, Cai XX. Hyperbaric oxygen therapy for post-stroke depression: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2020 Aug;195:105910.</span></span></span> |
| + | |||
| + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Reviewed by:</span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Michael Bennett 22/07/2021</span></span></span> | ||
| + | |||
| + | '''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">Update or delete by:</span></span></span>'''<span style="font-size:12.0pt"><span style="line-height:107%"><span style="font-family:">July 2024</span></span></span> | ||
| + | <p style="text-align: center;"> </p> <p style="text-align: center;">[[File:Sumhorsa.gif|center|Sumhorsa.gif]]</p> | ||
| + | = [[Stroke|BACK]] = | ||
Latest revision as of 01:05, 22 July 2021
Weak evidence that hyperbaric oxygen may be safe and effective for post-stroke depression.
Objectives:Post-stroke depression (PSD) is common consequence of stroke. However, today the majority of PSD patients remains untreated or inadequately treated, especially in the developing countries. Herein, we performed a meta-analysis to evaluate efficacy and safety of hyperbaric oxygen (HBOT) therapy for PSD.
Patients and methods:Seven electronic databases were comprehensively searched for randomized clinical trials (RCTs) from inception to May 2019. Outcome measures included response rate, depression severity, neurological deficit, physical disability and adverse events.
Results:A total of 27 RCTs involving 2250 participants were identified. Patients in HBOT group had a higher response rate than patients in control group (response rate: 69.4% vs 51.2%, odds ratio [OR]=2.51, 95% confidence interval [CI] [1.83–3.43], P =0.000).
HBO better for:
Hamilton Depression (HAMD) –17 item scores (weighted mean difference [WMD] =−4.33, 95% CI [−4.82 to −3.84], P=0.000)
HAMD-24 item scores (WMD=−4.31, 95% CI [−5.01 to −3.62], P=0.000)
National Institute of Health Stroke Scale (NIHSS) scores (WMD=−2.77, 95% CI [−3.57 to −1.98], P=0.000)
Chinese Stroke Scale (CSS) scores (WMD=−3.75, 95% CI [−5.12 to −2.38], P=0.000)
Modified Scandinavian Stroke Scale (MASSS) scores (WMD=−3.66, 95% CI [−6.26 to −1.06], P=0.000).
Barthel Index (WMD=10.68, 95% CI [7.98–13.37].
Patients with HBOT along with antidepressants treatment achieve superior results than patients with antidepressants monotherapy. Patients with HBOT monotherapy achieve a slightly higher response rate than patients with antidepressants monotherapy (OR=1.29, 95% CI [1.04–1.60], P=0.000). Besides, HBOT group reported less adverse events (9.6%vs16.6%, P < 0.05). The most frequent side-effect of HBOT is ear pain (26 cases).
Conclusion: Based on our pooled analysis, HBOT is effective and safe therapeutic approach for PSD. However, results should be cautiously interpreted due to a relatively poor methodological quality.
Comments:
1. MA dominated by Chinese studies unavailable to this reviewer to date. Only 1 of 27 included studies published in English and no studies from the Cochrane review are included. This may reflect the non-acute nature of interventions applied in the convalescent period rather than acute stroke.
2. Authors were only confident of randomisation in 8 of 27 studies and only 1 was blinded.Low quality RCTs likely
3. Conclusions are difficult to assess given the above. Some of the outcome measures apparently improved were assessing function (NIHSS) and QoL (Barthel Index).
Citation:Liang XX, Hao YG, Duan XM, Han XL, Cai XX. Hyperbaric oxygen therapy for post-stroke depression: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2020 Aug;195:105910.
Reviewed by:Michael Bennett 22/07/2021
Update or delete by:July 2024